Financial Performance - Revenues for the fiscal year 2026 reached $4,486 million, compared to $4,333 million in fiscal year 2025, reflecting a year-over-year increase of 3.5%[5] - Operating income for the fiscal year 2026 was $468 million, up from $282 million in fiscal year 2025, representing a significant increase of 66.1%[5] - Net income from continuing operations for the fiscal year 2026 was $311 million, compared to $147 million in fiscal year 2025, indicating a year-over-year growth of 111.6%[5] - Basic earnings per share for the fiscal year 2026 were $1.34, an increase from $1.05 in fiscal year 2025, marking a growth of 27.6%[5] - Revenues for the three months ended December 31, 2024, were reported at $4,333 million, with a gross margin of $1,797 million[7] - For the three months ended March 31, 2025, revenues increased to $4,480 million, with a gross margin of $1,861 million[8] - In the three months ended June 30, 2025, revenues further rose to $4,726 million, achieving a gross margin of $2,235 million[9] - Revenues for the three months ended September 30, 2025, were reported at $5,005 million, with an adjusted total also at $5,005 million[10] - For the twelve months ended September 30, 2025, revenues were $18,544 million, with adjusted revenues remaining the same[11] Operating Costs and Expenses - The company reported total operating costs and expenses of $4,018 million for the fiscal year 2026, compared to $4,051 million in fiscal year 2025, a decrease of 0.8%[5] - Research and development expenses for the fiscal year 2026 totaled $235 million, slightly down from $243 million in fiscal year 2025, showing a decrease of 3.3%[5] - Integration, restructuring, and transaction expenses amounted to $108 million in the fiscal year 2026, compared to $89 million in fiscal year 2025, reflecting an increase of 21.3%[5] - Research and development expenses were $243 million for the three months ended December 31, 2024, $232 million for March 31, 2025, and $230 million for June 30, 2025[7][8][9] - Selling and administrative expenses were $1,155 million for the three months ended December 31, 2024, $1,117 million for March 31, 2025, and $1,163 million for June 30, 2025[7][8][9] Adjusted Financial Metrics - The company reported a significant increase in gross margin percentage from 41.5% in Q4 2024 to 47.2% in Q2 2025[7][9] - Operating income for the three months was $536 million, adjusted to $1,292 million after accounting for various costs[10] - Net income from continuing operations for the quarter was $346 million, with an adjusted net income of $937 million[10] - Diluted earnings per share from continuing operations for the quarter were reported at $1.20, adjusted to $3.26[10] - Gross margin for the twelve months was $8,258 million, adjusted to $10,241 million[11] - Operating income for the twelve months was $1,941 million, adjusted to $4,666 million[11] - Net income from continuing operations for the year was $1,100 million, with an adjusted net income of $3,433 million[11] - Diluted earnings per share from continuing operations for the year were reported at $3.81, adjusted to $11.90[11] Regulatory and Compliance Costs - The company incurred costs related to European regulatory initiatives, which are considered one-off costs, impacting the comparability of earnings[1] - BD incurred charges of $297 million in fiscal year 2025 related to product liability and legal matters, impacting other operating expenses[13] - The company recognized $98 million and $38 million in product remediation costs in fiscal years 2025 and 2024, respectively, recorded in cost of products sold[13] - Costs incurred for compliance with the European Union Medical Device Regulation and In Vitro Diagnostic Medical Device Regulation are recorded in cost of products sold and research and development expenses[13] - The company reported $67 million in accruals in fiscal year 2024 related to Italian government medical device payback legislation, impacting revenues[13] Management Insights - Management emphasizes the importance of non-GAAP measures for understanding operational performance and trends, while cautioning that these measures may differ from those used by other companies[2] - The company has indicated ongoing investments in product development and market expansion strategies to drive future growth[7][8][9] Other Operating Costs - BD's costs associated with integration and restructuring activities are recorded under integration, restructuring, and transaction expenses[13] - BD's amortization expense, primarily recorded in cost of products sold, is related to purchase accounting for acquisitions[13] - The company incurred costs for the separation of its former Diabetes Care business, recorded under other operating expenses[13] - Charges related to pension settlement costs amounted to $38 million in fiscal year 2025, recorded in other expenses[13] - Transaction costs and financing impacts from the Advanced Patient Monitoring acquisition are recorded under integration, restructuring, and transaction expenses, as well as interest expense[13] - BD's adjustments to reported results reflect costs that are considered outside of underlying operational results, affecting period-to-period comparability[13]

BD Launches AI-Enabled Medication Dispensing System to the European Market Accessibility StatementSkip Navigation Advanced automation and connected data capabilities strengthen medication inventory control and enhance safety across pharmacy settings. FRANKLIN LAKES, N.J., April 1, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD® Pyxis™ Pro Dispensing Solution and BD® Incada™ Connected Care Platform in ...

Core Viewpoint - Wall Street is shifting focus towards undervalued Dividend Aristocrat stocks like PepsiCo, Hormel Foods, and Becton Dickinson, which are currently trading at steep discounts due to specific headwinds that are now subsiding [2][4]. Group 1: PepsiCo (PEP) - PepsiCo has faced challenges since mid-2023, primarily due to the impact of GLP-1 drugs, but the overall customer base remains intact [7]. - The stock is currently valued at 17 times forward earnings, which is considered low for a reliable Dividend Aristocrat [9]. - A potential catalyst for stock recovery includes lower Treasury yields, with a current dividend yield of 3.75% [10]. Group 2: Hormel Foods (HRL) - Hormel Foods' stock has declined over 52% in the past five years, with net income dropping from $1 billion in 2022 to $478 million in 2025, despite stable revenue of $12 billion [11][12]. - The acquisition of the Planters snack nut portfolio for $3.35 billion in 2021 negatively impacted the balance sheet, leading to significant debt and cash reduction [13]. - The stock is believed to have bottomed out, with a floor price at $22 and a dividend yield of 5.22%, offering long-term upside potential at 15 times forward earnings [15]. Group 3: Becton Dickinson (BDX) - Becton Dickinson's stock has been stagnant from 2018 to 2025, experiencing a 20% decline due to various challenges including tariffs and leadership changes [16]. - Analysts expect earnings per share (EPS) and revenue to recover starting from FY2027, making the stock attractive at 12 times forward earnings [17]. - The dividend yield stands at 2.69% with a payout ratio of 30%, indicating room for growth in dividends [17].

Core Viewpoint - Becton, Dickinson and Company (NYSE:BDX) is recognized as one of the most undervalued blue-chip stocks, with a recent price target adjustment reflecting its transition to a pure-play medtech model following a business spin-off [1][2]. Financial Performance - In Q1, Becton, Dickinson reported an adjusted EPS of $2.91, surpassing the consensus estimate of $2.81, with revenues of $5.3 billion compared to the expected $5.15 billion [4]. - The company’s stock trades at approximately 11.5 times forward earnings, which is significantly lower than the average of 20.4 times for its MedTech coverage universe [2]. Product Development - The company received FDA 510(k) clearance for the Surgiphor 1000mL, the first 1000 mL antimicrobial irrigation system designed for powered lavage, aimed at enhancing surgical efficiency and safety [3]. Strategic Direction - CEO Tom Polen emphasized that the results reflect a "stronger-than-expected" performance driven by execution and growth in key markets, indicating a full pivot to "New BD" with a focus on innovation, productivity, and long-term growth [4].

Group 1 - The core viewpoint of the article is that Embecta, a company spun off from BD, is strategically transforming from a diabetes-focused company to a broader medical delivery platform through its acquisition of a UK auto-injector firm for $199 million (approximately 1.4 billion RMB) [2][3] - The acquisition signals a shift in Embecta's strategy, moving from being a "diabetes injection expert" to a "broad medical delivery company" by incorporating auto-injector technology that can be used for various biopharmaceuticals and chronic disease treatments [6][8] Group 2 - The value of auto-injectors has become a focal point for mergers and acquisitions due to three main reasons: the rapid growth of biopharmaceuticals necessitating upgraded delivery methods, the deep integration of drug companies with delivery devices, and the strong platform potential for scaling [8][10] - The transaction structure indicates that about one-third of the acquisition price is performance-based, linked to the sales performance of the next-generation auto-injector platform (Aidaptus), highlighting an investment in the platform's future success rather than just current revenue [12][15] Group 3 - The article concludes that the auto-injector market, previously underestimated compared to other fields like surgical robotics and AI imaging, is gaining importance as biopharmaceuticals continue to grow, positioning drug delivery devices as critical components in the commercialization of drugs [16][17] - For Chinese companies, the challenge is not whether to enter the auto-injector market, but rather how to integrate into the core value chain of drug-device combinations [19][20]

Core Insights - Becton, Dickinson and Company (BDX) is recognized as one of the 13 undervalued dividend aristocrats to consider for investment [1] - BDX is a leading global medical technology company, focusing on innovation in medical essentials, connected care, biopharma systems, and interventional solutions [2] FDA Clearance and Product Innovation - BDX received FDA 510(k) clearance for its Surgiphor™ 1000mL irrigation system, designed for powered lavage procedures, which provides a standardized and sterile solution for wound care [3][4] - The Surgiphor™ portfolio now includes both manual and powered irrigation options, enhancing flexibility for healthcare providers [4] - The company aims for an adjusted EPS of $12.35 to $12.65 for FY 2026, indicating a projected growth of 6% at the midpoint compared to the previous year [4]

Core Viewpoint - Becton Dickinson (BDX) has experienced a decline in share price of approximately 4.5% since its last earnings report, underperforming the S&P 500, raising questions about future performance leading up to the next earnings release [1] Financial Performance - BDX reported adjusted earnings per share of $2.91 for Q1 fiscal 2026, a decrease of 15.2% year over year, but exceeding the Zacks Consensus Estimate by 3.4% [2] - GAAP earnings per share for the quarter was $1.34, reflecting an increase of 28.8% from the previous year [2] - Revenues for the first quarter were $5.25 billion, up 1.6% year over year, surpassing the Zacks Consensus Estimate by 2% [3] - New BD revenues, reflecting the separation of its Biosciences and Diagnostic Solutions business, were $4.49 billion, an increase of 3.5% on a reported basis [4] Segment Performance - The Medical Essentials segment reported revenues of $1.59 billion, up 0.6% year over year, while the Connected Care segment generated $1.13 billion, up 5.5% [5] - BioPharma Systems segment revenues were $429 million, up 2.7%, and the BD Interventional segment generated $1.33 billion, up 5.8% [6] - The BD Life Sciences segment saw revenues decline to $766 million, down 8.3% year over year [6] Geographic Performance - U.S. revenues improved by 2.6% year over year to $3.16 billion, while international revenues were $2.09 billion, up 0.2% on a reported basis but down 2.8% at constant exchange rates [7] Margin Analysis - Gross profit increased by 7.9% year over year to $2.41 billion, with gross margin expanding by 266 basis points to 45.9% [8] - Adjusted operating profit totaled $712 million, reflecting a 24% increase from the previous year, with an adjusted operating margin of 13.6% [9] Financial Position - At the end of Q1 fiscal 2026, BDX had cash and cash equivalents of $751 million, up from $649 million at the end of fiscal 2025, while total debt increased to $19.54 billion [10] - Net cash provided by continuing operating activities was $657 million, compared to $693 million a year ago [10] Dividend History - BDX has a consistent dividend-paying history, with a five-year annualized dividend growth rate of 5.47% [11] Fiscal Guidance - For fiscal 2026, BDX projects revenue growth above low single digits on a reported basis and anticipates adjusted earnings per share in the range of $12.35-$12.65, with the Zacks Consensus Estimate at $14.84 [12] Estimate Revisions - There has been a downward trend in estimates, with the consensus estimate shifting down by 16.86% [13] VGM Scores - BDX has an average Growth Score of C and a similar score for momentum, with a grade of B for value, placing it in the top 40% for value investors [14] Outlook - Estimates for BDX have been trending downward, leading to a Zacks Rank of 4 (Sell), indicating expectations of below-average returns in the coming months [15]

Core Viewpoint - The company does not anticipate any impact from oil prices or resin costs for the current fiscal year, attributing this stability to effective hedging strategies implemented in recent years [2]. Group 1: Oil and Resin Impact - The company has observed that the correlation between oil prices and resin costs has diminished, indicating a decoupling of these two factors [2]. - The company has implemented aggressive hedging strategies for both currency and oil, which has significantly mitigated potential financial impacts from fluctuations in resin prices [2]. - Even if oil prices remain stable or increase slightly, the financial impact on the company is projected to be in the low single-digit millions of dollars, which is considered negligible for the fiscal year [2]. Group 2: Future Monitoring - The company will continue to monitor oil prices and resin costs for future fiscal years, particularly looking ahead to FY '26, but currently sees no anticipated impact [2].

Core Viewpoint - The healthcare sector, often not associated with dividends, has notable dividend stocks like Becton, Dickinson and Medtronic that could be valuable additions to investment portfolios [1]. Group 1: Becton, Dickinson - Becton, Dickinson has increased its dividend annually for over 50 years, qualifying it as a Dividend King [2]. - The company operates in the medical-surgical business and medical device sectors, focusing on essential products like syringes [2]. - Despite recent execution challenges, Becton, Dickinson has a pipeline of new products and has completed a spinoff to enhance focus on growth [4]. - The current dividend yield is 2.4%, appealing to long-term dividend investors [4]. Group 2: Medtronic - Medtronic is nearing Dividend King status with a strong dividend history and a current yield of 2.9% [5]. - The company is also experiencing a weak period but is positioned for potential growth, particularly with its recent entry into the surgical robotics market [7]. - Medtronic's P/E ratio is 27x, significantly lower than the 63x of its competitor Intuitive Surgical, suggesting room for valuation improvement as it advances in surgical robotics [7][8]. Group 3: Investment Considerations - Both Becton, Dickinson and Medtronic are accessible for investors with smaller amounts, allowing for the purchase of multiple shares with $1,000 [9]. - The current market conditions present catalysts that may lead to higher valuations for both companies, making them timely investment opportunities [9].

Company Overview - Becton, Dickinson and Company (BDX) has received CE Mark approval in the European Union for its Revello Vascular Covered Stent, expanding its peripheral vascular portfolio and enhancing its position in the peripheral artery disease (PAD) treatment market [1][3]. Product Details - The Revello Vascular Covered Stent is designed for treating atherosclerotic lesions in the common and external iliac arteries, featuring a self-expanding nitinol stent with an ultrathin expanded polytetrafluoroethylene covering [6][7]. - The device includes a tri-axial delivery system for controlled deployment, an atraumatic tip for smoother insertion, and is available in various diameters and catheter lengths for procedural flexibility [8]. Market Potential - The global peripheral arterial disease treatment market is projected to grow from $3.17 billion in 2025 to approximately $6.11 billion by 2034, with a compound annual growth rate (CAGR) of 7.56% [10]. - The increasing prevalence of PAD among Europe's aging population is expected to drive demand for the Revello stent, allowing BD to capture more procedure volumes and expand its market share [3]. Recent Developments - BD has also received FDA 510(k) clearance for its Surgiphor 1000mL antimicrobial irrigation system, marking a significant addition to its product offerings [11]. - The company introduced the BD Vacutainer Urine Complete Cup Kit to enhance diagnostic testing efficiency [12]. - BD launched BD Research Cloud 7.0 to advance its AI strategy in flow cytometry and life sciences research [13].